How much funding has Vitae Pharmaceuticals raised?

Vitae Pharmaceuticals has raised $34.0M in total funding, most recently a Venture Round.

Who are Vitae Pharmaceuticals's investors?

Vitae Pharmaceuticals's investors include Allergan, Atlas Venture, Venrock, New Enterprise Associates.

When was Vitae Pharmaceuticals founded?

Vitae Pharmaceuticals was founded in 2001.

Where is Vitae Pharmaceuticals headquartered?

Vitae Pharmaceuticals is headquartered in Fort Washington, Pennsylvania, United States.

What industry is Vitae Pharmaceuticals in?

Vitae Pharmaceuticals operates in Biotech, Healthcare.

How many employees does Vitae Pharmaceuticals have?

Vitae Pharmaceuticals has 51-200 employees.

Vitae Pharmaceuticals

Acquired

Public · Fort Washington, United States · Founded 2001 · $34.0M raised

Biotech

Healthcare

Headquarters: Fort Washington, Pennsylvania
Employees: 51–200
Founded: 2001
Business Model: B2B

Total Funding: $34.0M
Last Round: $34.0M Venture RoundJan 2011
Rounds: 2
Type: Public

About

Vitae Pharmaceuticals (formerly Concurrent Pharmaceuticals) was a clinical-stage biopharmaceutical company founded in 2001 and headquartered in Fort Washington, Pennsylvania. The company pioneered structure-based and computational drug design, using its proprietary Contour platform to discover and develop novel small molecule therapeutics targeting difficult-to-drug proteins. Vitae built a portfolio of first-in-class drug candidates across therapeutic areas including dermatology, inflammation, and metabolic diseases. The company was publicly traded on the Nasdaq as VTAE and raised over $150 million before being acquired by Allergan in October 2016 for approximately $639 million. Its lead dermatology assets were integrated into Allergan's pipeline. One of its discovered compounds, revumenib (Revuforj), later received FDA approval in 2024 for acute leukemia.

Summary

Vitae Pharmaceuticals is a Biotech company based in Fort Washington, United States, founded in 2001. It has raised $34.0M in total across 2 rounds, most recently a $34.0M Venture Round round in Jan 2011. Investors include Allergan, Atlas Venture and Venrock.